Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022...
-
Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for...
-
EDINBURGH, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
-
EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
-
EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin...
-
NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Phase 1 Study Demonstrated Encouraging...
-
Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022 Data from First Interim Analysis May Support an NDA Submission in the United States under the...
-
EDINBURGH, United Kingdom, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
-
EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad...
-
EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer,...